

Please amend the claims as follows. Applicants have included herewith pages showing markups of the claims with insertions and deletions indicated by underlining and bracketing, respectively.

3.(amended) The method according to claim 1, wherein the RRF protein crystal is bipyramidal.

a 2

4.(amended) The method according to claim 1, wherein the RRF protein crystal has a space group P4<sub>1</sub>2<sub>1</sub>2<sub>1</sub> or a space group P4<sub>3</sub>2<sub>1</sub>2.

5. (amended)

5.(amended) The method according to claim 1, wherein the RRF protein crystal has a size of 0.3 × 0.3 × 0.5 mm.

6.(amended) The method according to claim 1, wherein the RRF protein crystal has respective unit lattices of a size of a=b=47.3Å and c=297.6Å.

7.(amended) The method according to claim 1, wherein the RRF protein crystal is characterized by a structure coordinate described in Table 7.

8.(amended) The method according to claim 1, wherein the RRF protein crystal is derived from Thermotoga maritima.

9.(amended) The method according to claim 1, wherein the RRF protein crystal is orthorhombic.

10.(amended) The method according to claim 1, wherein the RRF protein crystal has a space group P2<sub>1</sub>2<sub>1</sub>2.

11.(amended) The method according to claim 1, wherein the RRF protein crystal has a size of 30 × 50 × 250 µm.

12.(amended) The method according to claim 1, wherein the RRF protein crystal is derived from strain X.

13.(amended) The method according to claim 1, wherein the RRF protein crystal is crystallized by a drop-like vapour diffusion method.

14.(amended) The method according to claim 1, wherein the RRF protein crystal is a heavy atom derivative and the crystal is any crystal of the RRF protein itself, an RRF protein mutant, an RRF protein homologue or an RRF protein co-complex.

15.(amended) The method according to claim 14, wherein the heavy atom derivative is formed by reaction of a compound selected from the group consisting of thyromethal, gold thiomalate, uranyl acetate and lead chloride.

16.(amended) The method according to claim 1, wherein the RRF protein crystal is a heavy atom derivative of platinum or mercury.

17.(amended) The method according to claim 1, wherein the RRF protein is a monomer.

18.(amended) The method according to claim 1, wherein the RRF protein is characterized by amino acid displacement according to Table 5 or Table 6.

19.(amended) The method according to claim 1, wherein a compound characterized by the chemical entity bound to the active site, accessory binding site or pocket is an inhibitor to the RRF protein.

20.(amended) The method according to claim 19, wherein the inhibitor is a competitive inhibitor, an uncompetitive inhibitor or a noncompetitive inhibitor to the RRF protein.

21.(amended) The method according to claim 1, comprising determining orientation of a ligand at the active site or accessory binding site of the RRF protein.

*Q8  
Oenv*  
22.(amended) The method according to claim 1, wherein the structure coordinate is a structure coordinate of the RRF protein according to Table 7.

*AB*  
47.(amended) The method according to claim 1, wherein the pocket of the RRF protein is a pocket in the vicinity of C-terminal positioned on a folded part separating two domains of the RRF protein.

48.(amended) The method according to claim 1, wherein the compound inhibits binding of the RRF protein to ribosome or inhibits behavior of the RRF protein on the ribosome.

49.(amended) The inhibitor to an RRF protein, obtained by the method according to claim 19.

**Remarks**

Applicant has amended the specification to add priority claim information for the above-identified U.S. national stage application. Applicant has amended the claims to adjust claim dependencies, to correct typographical errors, and to reduce filing fees. No new matter has been added. Copies of the new section and amended claims are attached hereto on separate pages.

Respectfully submitted,

  
John R. Van Amsterdam, Reg. No. 40,212  
Attorneys for Applicants  
WOLF, GREENFIELD & SACKS, P.C.  
600 Atlantic Avenue  
Boston, MA 02210-2211  
(617) 720-3500

Attorney Docket No. K0448/7010  
Date: 4 December 2001  
**X12/04/01**